← Leaderboards
Khalil Ahmed
Minneapolis Va Medical Center
$3,124,257
Attributed
$3,124,257
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $296.5K · FY2005–24$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,124,257 · 3
VA$0 · 4
By mechanism
R01$2,019,091 · 2
U01$1,105,166 · 1
I01$0 · 3
IS1$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$257,543,614
- Charles A Coltman · Southwest Oncology Group$181,133,593
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Larry Arthur$62,719,328
- William J. Blot · Vanderbilt University$62,640,427
- Walter John Curran · Thomas Jefferson University$60,981,384
Research focus
ProstateInvestigationMalignant Neoplasm Of ProstateSignal TransductionMalignant NeoplasmsResponseCancer CellCasein Kinase IiCell DeathTranslationsNormal CellAndrogensAndrogen ReceptorCell PhysiologyApoptosisMediatingPhenotypeCell GrowthCessation Of LifeMolecularCellsLeadAgingCell Survival
Grant awards (26)
Dynamics of protein kinase CK2 signaling in prostate cancer pathogenesis$0
I01 · FY2024 · VA · contact PI
Dynamics of protein kinase CK2 signaling in prostate cancer pathogenesis$0
I01 · FY2023 · VA · contact PI
Dynamics of protein kinase CK2 signaling in prostate cancer pathogenesis$0
I01 · FY2022 · VA · contact PI
Dynamics of protein kinase CK2 signaling in prostate cancer pathogenesis$0
I01 · FY2021 · VA · contact PI
Mechanisms of CK2-regulated prostate cancer survival and death$0
I01 · FY2019 · VA · contact PI
ShEEP Request for NanoString nCounter® FLEX Analysis System$0
IS1 · FY2018 · VA · contact PI
Mechanisms of CK2-regulated prostate cancer survival and death$0
I01 · FY2018 · VA · contact PI
Mechanisms of CK2-regulated prostate cancer survival and death$0
I01 · FY2017 · VA · contact PI
Mechanisms of CK2-regulated prostate cancer survival and death$0
I01 · FY2016 · VA · contact PI
A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer$292,333
R01 · FY2015 · CA · contact PI
Modulation of Apoptosis in Prostate Cancer$0
I01 · FY2015 · VA · contact PI
A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer$283,563
R01 · FY2014 · CA · contact PI
Modulation of Apoptosis in Prostate Cancer$0
I01 · FY2014 · VA · contact PI
A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer$274,795
R01 · FY2013 · CA · contact PI
Modulation of Apoptosis in Prostate Cancer$0
I01 · FY2013 · VA · contact PI
A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer$293,483
R01 · FY2012 · CA · contact PI
Modulation of Apoptosis in Prostate Cancer$0
I01 · FY2012 · VA · contact PI
A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer$296,474
R01 · FY2011 · CA · contact PI
Studies of Normal and Neoplastic Prostate$215,048
U01 · FY2008 · CA · contact PI
Studies of Normal and Neoplastic Prostate$215,048
U01 · FY2007 · CA · contact PI
Studies of Normal and Neoplastic Prostate$221,470
U01 · FY2006 · CA · contact PI
Studies of Normal and Neoplastic Prostate$226,800
U01 · FY2005 · CA
Studies of Normal and Neoplastic Prostate$226,800
U01 · FY2004 · CA
NORMAL AND NEOPLASTIC PROSTATE$207,847
R01 · FY2002 · CA
NORMAL AND NEOPLASTIC PROSTATE$201,852
R01 · FY2001 · CA
NORMAL AND NEOPLASTIC PROSTATE$168,744
R01 · FY2000 · CA